Literature DB >> 11095863

Vaccination in HIV-infected Patients.

.   

Abstract

Nearly 20 years into the HIV pandemic, vaccination of HIV-infected persons remains controversial. Although vaccine-preventable diseases are common in HIV, concerns about vaccine safety and lack of efficacy in this setting often lead to missed opportunities for vaccination. In this article, we review the literature regarding vaccine risks and benefits and offer recommendations regarding their use and timing in HIV-infected persons.

Entities:  

Year:  2000        PMID： 11095863     DOI： 10.1007/s11908-000-0042-8

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.663


  83 in total

1.  Antibody response to Haemophilus influenzae type b vaccine in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus.

Authors:  F P Kroon; J T van Dissel; G T Rijkers; J Labadie; R van Furth
Journal:  Clin Infect Dis       Date:  1997-09       Impact factor: 9.079

2.  The effects of immunization in human immunodeficiency virus type 1 infection.

Authors:  C M Farber; A A Barath; T Dieye
Journal:  N Engl J Med       Date:  1996-09-12       Impact factor: 91.245

3.  Immunogenicity of influenza vaccine (1993-94 winter season) in HIV-seropositive and -seronegative ex-intravenous drug users.

Authors:  A M Iorio; A Alatri; D Francisci; R Preziosi; M Neri; I Donatelli; M R Castrucci; L R Biasio; C Tascini; R Iapoce; P Pierucci; F Baldelli
Journal:  Vaccine       Date:  1997-01       Impact factor: 3.641

4.  Measles and measles immunity in children infected with human immunodeficiency virus.

Authors:  K Krasinski; W Borkowsky
Journal:  JAMA       Date:  1989-05-05       Impact factor: 56.272

5.  Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination.

Authors:  A C Collier; L Corey; V L Murphy; H H Handsfield
Journal:  Ann Intern Med       Date:  1988-07-15       Impact factor: 25.391

6.  Invasive pneumococcal disease: clinical features, serotypes, and antimicrobial resistance patterns in cases involving patients with and without human immunodeficiency virus infection.

Authors:  R E Frankel; M Virata; C Hardalo; F L Altice; G Friedland
Journal:  Clin Infect Dis       Date:  1996-09       Impact factor: 9.079

7.  Influenza-associated morbidity and mortality in young and middle-aged women.

Authors:  K M Neuzil; G W Reed; E F Mitchel; M R Griffin
Journal:  JAMA       Date:  1999-03-10       Impact factor: 56.272

8.  Cell-mediated and humoral immune responses in children infected with human immunodeficiency virus during the first four years of life.

Authors:  W Borkowsky; M Rigaud; K Krasinski; T Moore; R Lawrence; H Pollack
Journal:  J Pediatr       Date:  1992-03       Impact factor: 4.406

9.  Pneumococcal vaccination in HIV-1-infected adults in Uganda: humoral response and two vaccine failures.

Authors:  N French; C F Gilks; A Mujugira; C Fasching; J O'Brien; E N Janoff
Journal:  AIDS       Date:  1998-09-10       Impact factor: 4.177

10.  Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1.

Authors:  S K Stanley; M A Ostrowski; J S Justement; K Gantt; S Hedayati; M Mannix; K Roche; D J Schwartzentruber; C H Fox; A S Fauci
Journal:  N Engl J Med       Date:  1996-05-09       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.